Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Chemokine’s Phase II liver cancer trial
The study will evaluate the efficacy and safety of CTCE-9908 administered at a dose of 5mg/kg. The primary end point will be to determine the response rate of
The study will evaluate the efficacy and safety of CTCE-9908 administered at a dose of 5mg/kg. The primary end point will be to determine the response rate of
According to the companies, the MilliPROBE system is the first solution of its kind for biopharmaceutical manufacturing. It combines Millipore’s sample prep methodologies with Gen-Probe’s advanced nucleic acid
Third Wave also announced that four well-known regional distributors have been secured to distribute its human papillomavirus (HPV) product in Italy. The company recently announced that its HPV
Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year. CP404 is a calcium
Under the terms of the agreement, Biogen Idec and PDL have granted Ophthotech worldwide development and commercial rights to all ophthalmic uses of volociximab (M200). Biogen Idec and
Clirophtha is a contract research organization in Europe and North America that is dedicated to ophthalmology clinical trials. Iris Pharma said that this merger establishes the first global
A Phase I study in healthy volunteers will be conducted in the US by a clinical research organization (CRO) in a Phase I unit. Can-Fite estimates that this
The grant from China’s Ministry of Science and Technology, awarded jointly to Shanghai Wanxing and Second Military Medical University (SMMU), is to support technology development as part of
According to the institute, Elesclomol has a completely new and distinct mechanism of action from other cancer therapies as it induces a potent stress response in cancer cells,
Primera’s new board of directors will be led by Laurence McCarthy as executive chairman and will include Martin Verhoef, president and CEO; Michael Bigham and Vincent Miles, Abingworth;